Objective:

To discuss the impact of the COVID-19 pandemic on the adoption of digital pathology and telepathology.

Approach:

• Current Limitations: Digital pathology has seen limited adoption due to regulatory hurdles, high costs, and workflow changes.
• Impact of COVID-19: The pandemic has necessitated remote work for pathologists, prompting a reevaluation of digital pathology's role in clinical practice.
• Regulatory Changes: The Department of Health and Human Services has allowed remote slide reviews, easing restrictions for pathologists.
• Future Implications: The shift towards telehealth in pathology may lead to lasting changes in practice patterns and regulatory oversight.

Key Findings:

• Digital pathology systems have been limited to non-regulatory areas like research and education.
• Only two digital imaging systems have received FDA approval since 2017.
• COVID-19 has created an urgent need for remote pathology services to protect healthcare workers and ensure patient care.

Interpretation:

Limitations:

• The article does not provide specific data on the effectiveness of remote pathology services.
• Future regulatory changes and their impacts remain uncertain.

Conclusion:

Sources:

• College of American Pathologists Report
• Centers for Medicare & Medicaid Services Guidance